Table 3.
The optimal cutoff value of peripheral zone prostate-specific antigen density, prostate-specific antigen, prostate-specific antigen density, and transition zone prostate-specific antigen density for predicting clinically significant prostate cancer
| PSA (ng ml−1) | Variable | Best cutoff | Sensitivity (%) | Specificity (%) | AUC-ROC |
|---|---|---|---|---|---|
| 4.0–10.0 | PZ-PSAD | 0.019 | 92.6 | 43.5 | 0.403 |
| PSA | 4.895 | 90.7 | 16.0 | 0.145 | |
| PSAD | 0.095 | 94.4 | 34.0 | 0.321 | |
| TZ-PSAD | 0.195 | 92.6 | 44.0 | 0.407 | |
| 10.1–20.0 | PZ-PSAD | 0.297 | 90.6 | 71.6 | 0.649 |
| PSA | 10.885 | 90.6 | 18.3 | 0.166 | |
| PSAD | 0.225 | 90.6 | 71.6 | 0.649 | |
| TZ-PSAD | 0.335 | 92.2 | 58.7 | 0.541 | |
| >20.0 | PZ-PSAD | 1.180 | 92.3 | 54.2 | 0.500 |
| PSA | 25.00 | 91.0 | 25.0 | 0.228 | |
| PSAD | 0.470 | 91.0 | 54.2 | 0.493 | |
| TZ-PSAD | 0.720 | 91.0 | 54.2 | 0.493 |
PSA: prostate-specific antigen; PSAD: prostate-specific antigen density; TZ-PSAD: transition zone prostate-specific antigen density; PZ-PSAD: peripheral zone prostate-specific antigen density; ROC: receiver operating characteristic; AUC-ROC: area under the ROC curve